Research Study

A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir for 12 Weeks in Subjects With Chronic HCV Infection Who Are on Dialysis for End Stage Renal Disease
Principal Investigator 
Eric M. Yoshida

Overview

Body Locations and Systems 
Hepatitis C
ClinicalTrials.gov# 
nct03036852
Status 
Recruiting
Study Start/End 
Jul 24, 2017 to May 1, 2020
Locations 
Vancouver General Hospital
Name/Title 
Jo-Ann Ford
Phone 
604-875-5705
Purpose of Study 

The primary objectives of this study are to evaluate safety, efficacy and tolerability of treatment with sofosbuvir (Sovaldi®)/velpatasvir (Epclusa®; SOF/VEL) for 12 weeks in adults with chronic hepatitis C virus (HCV) infection who are on dialysis for End Stage Renal Disease (ESRD).

Eligibility 

See Clinicaltrials.gov

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.